Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.

Similar stories